Tandem Diabetes Care Logo
US8753722037
A2H5BX
TNDM

Tandem Diabetes Care

Loading quotes...

Forecast

The analysts' average price target is €21.07 (+32.10%). The median is €18.63 (+16.80%).

Buy
  23
Hold
  16
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Tandem Diabetes relies on pharmacy model, Mobi‑Patch and international direct sales for growth

    Tandem Diabetes unveiled a long-term growth plan that includes a pharmacy-based pay-as-you-go model in the US, broader rollout of the tubeless Mobi‑Patch pump in the second half of 2026, and expansion of direct sales activities in selected international markets. The new US model is intended to remove the initial cost barrier for patients and bring up to 80% of US sales through pharmacies; internationally, the company expects higher prices and better follow-on care via direct business. New patient starts stalled in the second quarter, but Tandem expects growth in the second half of the year driven by product dynamics, seasonal demand and additional PBM coverage. At the same time, the company is advancing automation projects, including development toward a fully closed‑loop insulin system and integration of existing CGM technologies. » More on de.investing.com


  • Tandem Diabetes Care beats profit forecasts, shares fall after slight revenue miss

    Tandem Diabetes Care reported adjusted EPS of -$0.31 for Q2, beating the analyst estimate of -$0.33, while revenue of $254.6 million missed estimates only slightly. Gross margin rose to 57% and adjusted EBITDA margin reached 3%, marking the fourth consecutive positive quarter. Management reaffirmed the full-year outlook, highlighted record shipments and progress in pharmacy distribution, and expects approval of Mobi Tubeless in the second half of 2026. The stock fell about 4.1% in regular trading and recovered slightly in after-hours trading. » More on de.investing.com


  • Tandem Diabetes Care lags after reimbursement shift clouds near-term revenue

    Meridian Small Cap Growth Fund said Tandem Diabetes Care underperformed in Q2 as its transition to a pharmacy-based, pay-as-you-go reimbursement model reduced near-term revenue visibility and second-quarter guidance missed expectations. The fund noted added caution from a new competing patch-pump entrant and that Tandem’s lower-beta profile lagged in a market favoring high-beta names. Meridian remains invested, citing the company’s differentiated pump technology, growing installed base and recurring supply revenue, and views the reimbursement change as a long-term positive. » More on finance.yahoo.com


  • Tandem Diabetes receives CE marking for expanded pump indications in Europe

    Tandem Diabetes has received CE approval in Europe for its automated insulin delivery systems t:slim X2 and Tandem Mobi with Control‑IQ+ for use in pregnant people with Type 1 diabetes and in adults with Type 2 diabetes. The stock rose nearly 8% on the news and the company posted a weekly gain of 13%; market capitalization about $1.33 billion. The approval is based on the CIRCUIT study (improved time in range for pregnant people) and the 2IQP study (HbA1c reductions in Type 2 diabetes). The t:slim X2 is already available in several countries; Tandem Mobi is slated for H2 2026 launch. Analysts do not expect the company to be profitable this year. » More on de.investing.com


  • Tandem Diabetes Care reports record revenue for Q1 2026, stock falls sharply

    Tandem Diabetes Care posted record revenue of $247.22 million in Q1 2026 and beat expectations with an EPS of -0.30 versus -0.44 expected. Gross margin improved to 55% and operating margin to -7%, and free cash flow of $5 million was generated. Despite the positive metrics, the stock fell about 14% in after-hours trading; the company plans product launches and international expansion in the second quarter. Management cites the integration of FreeStyle Libre 3 Plus and the international rollout of Tandem Mobi as growth drivers. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2023, Tandem Diabetes Care has already paid €1.14 in dividends. The last payout was in April 2023.

Financials

In the last quarter, Tandem Diabetes Care had revenue of €250.46M and net profit of -€6.25M
(EUR) September 2026
YoY
Revenue 250.46M 17.92%
Gross profit 141.63M 23.76%
Net profit -6.25M 65.32%
EBITDA -772.49K 95.12%

Fundamentals

Metric Value
Market capitalization
€1.27B
Number of shares
69.79M
52-week high/low
€26.94 - €11.14
Dividends No
Beta
1.60
P/E ratio
-27.93
PEG ratio
-0.18
P/B ratio
10.35
P/S ratio
1.30

Company profile

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Name
Tandem Diabetes Care
CEO
John F. Sheridan
Headquarters San Diego, ca
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
11/14/2013
Employees 2,500

Ticker symbols

Exchange Symbol
NASDAQ
TNDM
Frankfurt
TD5A.F
DĂĽsseldorf
TD5A.DU
London
0M0F.L
MĂĽnchen
TD5A.MU
🍪

Parqet  uses cookies. Learn more